8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Feb 3, 2026·SEC
Pfizer Inc.(PFE)Earnings, Financials & Key Ratios
PFE•NYSE
18.5× P/E·Price updated Jun 19, 2026
AboutPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.Show more
- Revenue$62.58B-1.6%
- EBITDA$20.34B-13.4%
- Net Income$7.77B-3.1%
- EPS (Diluted)1.36-3.5%
- Gross Margin70.33%+6.9%
- EBITDA Margin32.51%-12.0%
- Operating Margin24.67%-4.8%
- Net Margin12.42%-1.5%
- ROE8.87%-1.7%
PFE Key Insights
Pfizer Inc. (PFE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓15 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 17.4%
✗Weaknesses
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PFE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PFE Price & Volume
Pfizer Inc. (PFE) stock price & volume — 10-year historical chart
Loading chart...
PFE Growth Metrics
Pfizer Inc. (PFE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.51%
5 Years8.48%
3 Years-14.56%
TTM1.36%
Profit CAGR
10 Years1.1%
5 Years-3.24%
3 Years-37.2%
TTM-4.78%
EPS CAGR
10 Years2.02%
5 Years-3.51%
3 Years-37.12%
TTM-5.05%
Return on Capital
10 Years10.75%
5 Years12.56%
3 Years7.22%
Last Year9.04%
PFE Recent Earnings
Pfizer Inc. (PFE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.75+3.9%
$0.72
Rev
$14.5B+4.4%
$13.8B
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$0.66+16.4%
$0.57
Rev
$17.6B+4.2%
$16.8B
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.87+37.4%
$0.63
Rev
$16.7B+0.9%
$16.5B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.78+34.5%
$0.58
Rev
$14.7B+8.1%
$13.6B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.75vs $0.72+3.9% | $14.5Bvs $13.8B+4.4% |
| Q1 2026 | Feb 3, 2026 | $0.66vs $0.57+16.4% | $17.6Bvs $16.8B+4.2% |
| Q4 2025 | Nov 4, 2025 | $0.87vs $0.63+37.4% | $16.7Bvs $16.5B+0.9% |
| Q3 2025 | Aug 5, 2025 | $0.78vs $0.58+34.5% | $14.7Bvs $13.6B+8.1% |
Based on last 12 quarters of dataView full earnings history →
PFE Peer Comparison
Pfizer Inc. (PFE) competitors in Vaccines and plasma-derived therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare PFE vs Peers
Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PFE Income Statement
Pfizer Inc. (PFE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 52.55B | 53.65B | 41.17B | 41.65B | 81.29B | 100.33B | 59.55B | 63.63B | 62.58B | 63.31B |
Revenue Growth % | -0.53% | 2.1% | -23.25% | 1.16% | 95.16% | 23.43% | -40.64% | 6.84% | -1.65% | 1.36% |
Cost of Goods Sold | 15.78B | 16.01B | 12.62B | 11.77B | 34.41B | 38.24B | 29.21B | 21.78B | 18.57B | 19.41B |
COGS % of Revenue | 30.03% | 29.84% | 30.66% | 28.26% | 42.33% | 38.11% | 49.05% | 34.23% | 29.67% | - |
Gross Profit | 36.77B▲ 0% | 37.64B▲ 2.4% | 28.55B▼ 24.2% | 29.88B▲ 4.7% | 46.88B▲ 56.9% | 62.09B▲ 32.5% | 30.34B▼ 51.1% | 41.85B▲ 37.9% | 44.01B▲ 5.2% | 43.91B▲ 0% |
Gross Margin % | 69.97% | 70.16% | 69.34% | 71.74% | 57.67% | 61.89% | 50.95% | 65.77% | 70.33% | 69.35% |
Gross Profit Growth % | -0.27% | 2.37% | -24.15% | 4.66% | 56.88% | 32.46% | -51.14% | 37.92% | 5.18% | - |
Operating Expenses | 22.38B | 22.35B | 21.04B | 20.8B | 26.08B | 24.54B | 25.05B | 25.36B | 28.58B | 29.06B |
OpEx % of Revenue | 42.59% | 41.66% | 51.1% | 49.93% | 32.09% | 24.46% | 42.06% | 39.86% | 45.67% | - |
Selling, General & Admin | 14.73B | 14.38B | 12.67B | 11.4B | 12.25B | 13.12B | 14.47B | 14.73B | 13.35B | 13.28B |
SG&A % of Revenue | 28.04% | 26.81% | 30.78% | 27.37% | 15.07% | 13.07% | 24.3% | 23.15% | 21.33% | - |
Research & Development | 7.64B | 7.97B | 8.36B | 9.39B | 13.83B | 11.43B | 10.58B | 10.74B | 11.98B | 12.42B |
R&D % of Revenue | 14.55% | 14.85% | 20.31% | 22.56% | 17.01% | 11.39% | 17.76% | 16.88% | 19.14% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -105M | 3.25B | 3M |
Operating Income | 14.39B▲ 0% | 15.29B▲ 6.2% | 7.51B▼ 50.9% | 9.09B▲ 21.0% | 20.79B▲ 128.9% | 37.55B▲ 80.6% | 5.29B▼ 85.9% | 16.48B▲ 211.5% | 15.44B▼ 6.3% | 14.85B▲ 0% |
Operating Margin % | 27.39% | 28.5% | 18.24% | 21.81% | 25.58% | 37.43% | 8.89% | 25.91% | 24.67% | 23.45% |
Operating Income Growth % | 0.82% | 6.24% | -50.87% | 20.96% | 128.87% | 80.58% | -85.91% | 211.47% | -6.35% | - |
EBITDA | 20.66B | 21.67B | 13.31B | 13.77B | 25.98B | 42.61B | 11.58B | 23.5B | 20.34B | 21B |
EBITDA Margin % | 39.32% | 40.4% | 32.32% | 33.05% | 31.97% | 42.47% | 19.45% | 36.93% | 32.51% | 33.17% |
EBITDA Growth % | 3.14% | 4.9% | -38.61% | 3.46% | 88.75% | 64% | -72.82% | 102.87% | -13.42% | -12.82% |
D&A (Non-Cash Add-back) | 6.27B | 6.38B | 5.79B | 4.68B | 5.19B | 5.06B | 6.29B | 7.01B | 4.91B | 6.16B |
EBIT | 13.57B | 13.2B | 13.06B | 8.49B | 25.6B | 35.97B | 3.27B | 11.11B | 10.19B | 10.79B |
Net Interest Income | -879M | -983M | -1.35B | -1.38B | -1.25B | -987M | -585M | -2.55B | -2.07B | -2.11B |
Interest Income | 391M | 333M | 225M | 73M | 36M | 251M | 1.62B | 545M | 603M | 575M |
Interest Expense | 1.27B | 1.32B | 1.57B | 1.45B | 1.29B | 1.24B | 2.21B | 3.09B | 2.67B | 2.69B |
Other Income/Expense | -2.09B | -3.4B | 3.97B | -2.05B | 3.52B | -2.82B | -4.23B | -8.46B | -7.92B | -6.94B |
Pretax Income | 12.3B▲ 0% | 11.88B▼ 3.4% | 11.48B▼ 3.4% | 7.04B▼ 38.7% | 24.31B▲ 245.5% | 34.73B▲ 42.9% | 1.06B▼ 97.0% | 8.02B▲ 658.3% | 7.52B▼ 6.3% | 7.91B▲ 0% |
Pretax Margin % | 23.42% | 22.15% | 27.9% | 16.89% | 29.91% | 34.61% | 1.78% | 12.61% | 12.02% | 12.49% |
Income Tax | -9.05B | 706M | 618M | 370M | 1.85B | 3.33B | -1.11B | -28M | -266M | 384M |
Effective Tax Rate % | -73.53% | 5.94% | 5.38% | 5.26% | 7.62% | 9.58% | -105.29% | -0.35% | -3.54% | 4.86% |
Net Income | 21.3B▲ 0% | 11.15B▼ 47.7% | 16.27B▲ 45.9% | 9.16B▼ 43.7% | 22.15B▲ 141.8% | 31.36B▲ 41.6% | 2.13B▼ 93.2% | 8.02B▲ 276.0% | 7.77B▼ 3.1% | 7.49B▲ 0% |
Net Margin % | 40.55% | 20.79% | 39.52% | 21.99% | 27.25% | 31.26% | 3.58% | 12.6% | 12.42% | 11.83% |
Net Income Growth % | 195.29% | -47.65% | 45.91% | -43.72% | 141.81% | 41.62% | -93.2% | 276% | -3.12% | -4.78% |
Net Income (Continuing) | 21.35B | 11.18B | 10.87B | 6.67B | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B | 7.52B |
Discontinued Operations | -1M | 10M | 5.43B | 2.53B | -268M | -1M | 0 | 11M | 25M | 0 |
Minority Interest | 348M | 351M | 303M | 235M | 262M | 256M | 274M | 294M | 299M | 303M |
EPS (Diluted) | 3.52▲ 0% | 1.87▼ 46.9% | 2.87▲ 53.7% | 1.63▼ 43.3% | 3.88▲ 138.6% | 5.47▲ 41.0% | 0.37▼ 93.2% | 1.41▲ 279.8% | 1.36▼ 3.5% | 1.31▲ 0% |
EPS Growth % | 200.58% | -46.94% | 53.67% | -43.29% | 138.58% | 41.01% | -93.22% | 279.85% | -3.55% | -5.05% |
EPS (Basic) | 3.57 | 1.90 | 2.92 | 1.65 | 3.95 | 5.59 | 0.38 | 1.42 | 1.36 | - |
Diluted Shares Outstanding | 6.06B | 5.98B | 5.67B | 5.63B | 5.71B | 5.73B | 5.71B | 5.7B | 5.69B | 5.73B |
Basic Shares Outstanding | 5.97B | 5.87B | 5.57B | 5.55B | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B | 5.69B |
Dividend Payout Ratio | 35.95% | 71.53% | 49.43% | 92.15% | 39.41% | 28.64% | 433.52% | 118.6% | 125.75% | - |
PFE Balance Sheet
Pfizer Inc. (PFE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 41.14B | 49.93B | 32.8B | 35.07B | 59.69B | 51.26B | 43.33B | 50.36B | 42.9B | 42.82B |
Cash & Short-Term Investments | 19.99B | 18.83B | 9.65B | 12.22B | 31.07B | 22.73B | 12.69B | 20.48B | 13.6B | 13.07B |
Cash Only | 1.34B | 1.14B | 1.12B | 1.79B | 1.94B | 416M | 2.85B | 1.04B | 1.14B | 1.7B |
Short-Term Investments | 18.65B | 17.69B | 8.53B | 10.44B | 29.13B | 22.32B | 9.84B | 19.43B | 12.45B | 11.37B |
Accounts Receivable | 11.27B | 11.4B | 9.51B | 11.18B | 15.74B | 14.53B | 15.54B | 14.78B | 11.87B | 12.59B |
Days Sales Outstanding | 78.29 | 77.56 | 84.29 | 97.95 | 70.7 | 52.86 | 95.27 | 84.77 | 69.26 | 73.21 |
Inventory | 7.58B | 7.51B | 7.07B | 8.05B | 9.06B | 8.98B | 10.19B | 10.85B | 10.65B | 10.67B |
Days Inventory Outstanding | 175.32 | 171.19 | 204.37 | 249.49 | 96.08 | 85.72 | 127.31 | 181.84 | 209.46 | 209.03 |
Other Current Assets | 2.3B | 12.19B | 6.58B | 3.65B | 3.82B | 5.02B | 4.91B | 4.25B | 6.77B | 2.91B |
Total Non-Current Assets | 130.65B | 109.5B | 134.69B | 119.16B | 121.78B | 145.94B | 183.17B | 163.04B | 165.26B | 164.8B |
Property, Plant & Equipment | 13.87B | 13.38B | 12.97B | 13.74B | 14.88B | 16.27B | 18.94B | 18.39B | 21.53B | 19.4B |
Fixed Asset Turnover | 3.79x | 4.01x | 3.17x | 3.03x | 5.46x | 6.17x | 3.14x | 3.46x | 2.91x | 3.22x |
Goodwill | 55.95B | 53.41B | 48.2B | 49.56B | 49.21B | 51.38B | 67.78B | 68.53B | 71.26B | 71.41B |
Intangible Assets | 48.74B | 35.21B | 33.94B | 28.34B | 25.15B | 43.37B | 64.9B | 55.41B | 53.73B | 52.56B |
Long-Term Investments | 7.01B | 2.77B | 20.15B | 20.26B | 21.53B | 15.07B | 15.37B | 2.23B | 1.74B | 5.72B |
Other Non-Current Assets | 3.23B | 2.8B | 17.63B | 4.57B | 7.68B | 13.16B | 12.47B | 9.82B | 7.3B | 9.84B |
Total Assets | 171.8B▲ 0% | 159.42B▼ 7.2% | 167.49B▲ 5.1% | 154.23B▼ 7.9% | 181.48B▲ 17.7% | 197.21B▲ 8.7% | 226.5B▲ 14.9% | 213.4B▼ 5.8% | 208.16B▼ 2.5% | 207.62B▲ 0% |
Asset Turnover | 0.31x | 0.34x | 0.25x | 0.27x | 0.45x | 0.51x | 0.26x | 0.30x | 0.30x | 0.30x |
Asset Growth % | 0.11% | -7.2% | 5.06% | -7.92% | 17.67% | 8.67% | 14.85% | -5.79% | -2.45% | -12.22% |
Total Current Liabilities | 30.43B | 31.86B | 37.3B | 25.92B | 42.67B | 42.14B | 47.79B | 42.99B | 36.98B | 34.35B |
Accounts Payable | 4.66B | 4.67B | 3.89B | 4.28B | 5.58B | 6.81B | 6.71B | 5.63B | 5.24B | 4.51B |
Days Payables Outstanding | 107.72 | 106.57 | 112.39 | 132.81 | 59.16 | 64.99 | 83.84 | 94.4 | 103.02 | 93.73 |
Short-Term Debt | 9.94B | 8.84B | 16.19B | 2.7B | 2.24B | 2.93B | 10.35B | 6.95B | 3.48B | 3.89B |
Deferred Revenue (Current) | 0 | 0 | 0 | 1.11B | 3.07B | 2.52B | 2.7B | 1.51B | 784M | 2.83B |
Other Current Liabilities | 13.32B | 15.04B | 14.14B | 14.61B | 28.27B | 25.98B | 23.32B | 23.2B | 18.32B | 20.11B |
Current Ratio | 1.35x | 1.57x | 0.88x | 1.35x | 1.40x | 1.22x | 0.91x | 1.17x | 1.16x | 1.25x |
Quick Ratio | 1.10x | 1.33x | 0.69x | 1.04x | 1.19x | 1.00x | 0.69x | 0.92x | 0.87x | 0.94x |
Cash Conversion Cycle | 145.89 | 142.17 | 176.27 | 214.63 | 107.62 | 73.59 | 138.74 | 172.21 | 175.7 | 188.5 |
Total Non-Current Liabilities | 69.71B | 63.81B | 66.84B | 64.84B | 61.34B | 59.15B | 89.42B | 81.9B | 84.4B | 82.87B |
Long-Term Debt | 32.67B | 32.91B | 34.65B | 35.57B | 34.76B | 31.93B | 60.5B | 57.41B | 61.64B | 60.56B |
Capital Lease Obligations | -27B | -21.35B | 1.03B | 0 | 0 | 0 | 0 | 2.29B | 2.29B | 2.29B |
Deferred Tax Liabilities | 3.9B | 3.7B | 5.58B | 4.06B | 349M | 1.02B | 640M | 2.12B | 2.4B | 9.76B |
Other Non-Current Liabilities | 33.15B | 27.2B | 26.54B | 25.2B | 26.24B | 26.2B | 28.28B | 20.09B | 18.07B | 19.89B |
Total Liabilities | 100.14B | 95.66B | 104.15B | 90.76B | 104.01B | 101.29B | 137.21B | 124.9B | 121.39B | 117.21B |
Total Debt | 42.61B | 41.74B | 50.84B | 38.27B | 37B | 34.86B | 70.84B | 66.99B | 67.42B | 64.45B |
Net Debt | 41.26B | 40.61B | 49.72B | 36.49B | 35.05B | 34.44B | 67.99B | 65.95B | 66.27B | 62.75B |
Debt / Equity | 0.59x | 0.65x | 0.80x | 0.60x | 0.48x | 0.36x | 0.79x | 0.76x | 0.78x | 0.71x |
Debt / EBITDA | 2.06x | 1.93x | 3.82x | 2.78x | 1.42x | 0.82x | 6.12x | 2.85x | 3.31x | 3.07x |
Net Debt / EBITDA | 2.00x | 1.87x | 3.74x | 2.65x | 1.35x | 0.81x | 5.87x | 2.81x | 3.26x | 2.99x |
Interest Coverage | 10.69x | 10.03x | 8.30x | 5.86x | 19.83x | 29.05x | 1.48x | 3.60x | 3.82x | 4.02x |
Total Equity | 71.66B▲ 0% | 63.76B▼ 11.0% | 63.45B▼ 0.5% | 63.47B▲ 0.0% | 77.46B▲ 22.0% | 95.92B▲ 23.8% | 89.29B▼ 6.9% | 88.5B▼ 0.9% | 86.78B▼ 1.9% | 90.4B▲ 0% |
Equity Growth % | 19.75% | -11.02% | -0.49% | 0.04% | 22.04% | 23.82% | -6.91% | -0.89% | -1.95% | -0.44% |
Book Value per Share | 11.83 | 10.67 | 11.18 | 11.27 | 13.57 | 16.73 | 15.64 | 15.53 | 15.26 | 15.77 |
Total Shareholders' Equity | 71.31B | 63.41B | 63.14B | 63.24B | 77.2B | 95.66B | 89.01B | 88.2B | 86.48B | 90.1B |
Common Stock | 464M | 467M | 468M | 470M | 473M | 476M | 478M | 480M | 481M | 482M |
Retained Earnings | 85.29B | 89.55B | 97.67B | 96.77B | 103.39B | 125.66B | 118.35B | 116.72B | 114.61B | 117.24B |
Treasury Stock | -89.42B | -101.61B | -110.8B | -110.99B | -111.36B | -113.97B | -114.49B | -114.76B | -115.02B | -115.19B |
Accumulated OCI | -9.32B | -11.28B | -11.64B | -11.69B | -5.9B | -8.3B | -7.96B | -7.84B | -8.07B | -7.2B |
Minority Interest | 348M | 351M | 303M | 235M | 262M | 256M | 274M | 294M | 299M | 303M |
PFE Cash Flow Statement
Pfizer Inc. (PFE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 16.47B | 15.83B | 12.59B | 14.4B | 32.58B | 29.27B | 8.7B | 12.74B | 11.71B | 11.98B |
Operating CF Margin % | 31.34% | 29.5% | 30.57% | 34.58% | 40.08% | 29.17% | 14.61% | 20.03% | 18.7% | - |
Operating CF Growth % | 3.58% | -3.9% | -20.46% | 14.42% | 126.2% | -10.17% | -70.27% | 46.48% | -8.15% | 27.46% |
Net Income | 21.36B | 11.19B | 16.3B | 7.02B | 22.46B | 31.4B | 2.17B | 8.05B | 7.75B | 7.49B |
Depreciation & Amortization | 6.27B | 6.38B | 6.01B | 4.78B | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B | 6.59B |
Stock-Based Compensation | 840M | 949M | 718M | 756M | 1.18B | 872M | 525M | 877M | 0 | 676M |
Deferred Taxes | -2.41B | -2.21B | 614M | -1.47B | -4.29B | -3.76B | -3.44B | -2.1B | -2.13B | -1.48B |
Other Non-Cash Items | -10.88B | 437M | -7.03B | 3.59B | -4.76B | 150M | 5.33B | 1.97B | 4.85B | -3.06B |
Working Capital Changes | 1.3B | -926M | -4.03B | -275M | 12.8B | -4.46B | -2.17B | -3.07B | -5.35B | 1.74B |
Change in Receivables | 259M | -644M | -742M | -1.25B | -3.81B | 261M | 347M | -109M | -263M | 0 |
Change in Inventory | -357M | -717M | -1.05B | -736M | -1.13B | 592M | 6.2B | -854M | 561M | 0 |
Change in Payables | 46M | 431M | -564M | 353M | 1.24B | 1.19B | -300M | -1.02B | -469M | 0 |
Cash from Investing | -4.74B | 4.53B | -3.94B | -4.27B | -22.55B | -15.78B | -32.28B | 2.65B | -1.35B | -3.84B |
Capital Expenditures | -2.22B | -2.2B | -2.59B | -2.79B | -2.71B | -3.24B | -3.91B | -2.91B | -2.63B | -2.5B |
CapEx % of Revenue | 4.22% | 4.09% | 6.3% | 6.7% | 3.34% | 3.23% | 6.56% | 4.57% | 4.2% | 3.95% |
Acquisitions | -1B | 154M | -10.86B | -621M | -12M | -23B | -43.43B | 7.04B | -6.93B | -13.24B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 650M | 133M | 206M | 813M | -306M | 3.77B | -180M | 0 | 165M | -904M |
Cash from Financing | -13.04B | -20.44B | -8.48B | -9.65B | -9.82B | -14.83B | 26.07B | -17.14B | -10.3B | -7.93B |
Debt Issued (Net) | -941M | -935M | 8.76B | -12.76B | -1.1B | -3.52B | 35.95B | -7.16B | -74M | 2.23B |
Equity Issued (Net) | -5B | -10.94B | -8.87B | 0 | 0 | -2B | 0 | 0 | 0 | 0 |
Dividends Paid | -7.66B | -7.98B | -8.04B | -8.44B | -8.73B | -8.98B | -9.25B | -9.51B | -9.77B | -9.78B |
Share Repurchases | -5B | -12.2B | -8.87B | 0 | 0 | -2B | 0 | 0 | 0 | 0 |
Other Financing | 250M | -589M | -341M | 11.55B | 16M | -335M | -632M | -469M | -459M | -386M |
Net Change in Cash | -1.25B▲ 0% | -206M▲ 83.6% | -50M▲ 75.7% | 475M▲ 1050.0% | 158M▼ 66.7% | -1.51B▼ 1058.9% | 2.45B▲ 261.7% | -1.81B▼ 173.9% | 99M▲ 105.5% | 275M▲ 0% |
Free Cash Flow | 14.25B▲ 0% | 13.63B▼ 4.4% | 9.99B▼ 26.7% | 11.61B▲ 16.2% | 29.87B▲ 157.2% | 26.03B▼ 12.8% | 4.79B▼ 81.6% | 9.84B▲ 105.2% | 9.08B▼ 7.7% | 9.48B▲ 0% |
FCF Margin % | 27.12% | 25.41% | 24.27% | 27.88% | 36.74% | 25.95% | 8.05% | 15.46% | 14.5% | 14.98% |
FCF Growth % | 2.52% | -4.36% | -26.68% | 16.19% | 157.23% | -12.85% | -81.59% | 105.2% | -7.72% | -15.47% |
FCF per Share | 2.35 | 2.28 | 1.76 | 2.06 | 5.23 | 4.54 | 0.84 | 1.73 | 1.60 | 1.65 |
FCF Conversion (FCF/Net Income) | 0.77x | 1.42x | 0.77x | 1.57x | 1.47x | 0.93x | 4.08x | 1.59x | 1.51x | 1.27x |
Interest Paid | 1.52B | 1.31B | 1.59B | 1.64B | 1.47B | 1.44B | 2.21B | 3.23B | 0 | 1.7B |
Taxes Paid | 2.49B | 3.65B | 3.66B | 3.15B | 7.43B | 7.87B | 3.15B | 3.6B | 0 | 3.59B |
PFE Key Ratios
Pfizer Inc. (PFE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 32.4% | 16.47% | 25.59% | 14.43% | 31.43% | 36.18% | 2.3% | 9.02% | 8.87% | 8.34% |
Return on Invested Capital (ROIC) | 10.22% | 10.55% | 5.18% | 6.39% | 14.68% | 23.19% | 2.76% | 7.93% | 7.53% | 7.31% |
Gross Margin | 69.97% | 70.16% | 69.34% | 71.74% | 57.67% | 61.89% | 50.95% | 65.77% | 70.33% | 69.35% |
Net Margin | 40.55% | 20.79% | 39.52% | 21.99% | 27.25% | 31.26% | 3.58% | 12.6% | 12.42% | 11.83% |
Debt / Equity | 0.59x | 0.65x | 0.80x | 0.60x | 0.48x | 0.36x | 0.79x | 0.76x | 0.78x | 0.71x |
Interest Coverage | 10.69x | 10.03x | 8.30x | 5.86x | 19.83x | 29.05x | 1.48x | 3.60x | 3.82x | 4.02x |
FCF Conversion | 0.77x | 1.42x | 0.77x | 1.57x | 1.47x | 0.93x | 4.08x | 1.59x | 1.51x | 1.27x |
Revenue Growth | -0.53% | 2.1% | -23.25% | 1.16% | 95.16% | 23.43% | -40.64% | 6.84% | -1.65% | 1.36% |
Related:PFE Dividend History·PFE Revenue History·PFE Price History·PFE P/E History·PFE Financial Ratios·PFE Institutional Holders
PFE SEC Filings & Documents
Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)
PFE Frequently Asked Questions
Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pfizer Inc. (PFE) reported $63.31B in revenue for fiscal year 2025. This represents a 460% increase from $11.31B in 1996.
Pfizer Inc. (PFE) saw revenue decline by 1.6% over the past year.
Yes, Pfizer Inc. (PFE) is profitable, generating $7.49B in net income for fiscal year 2025 (12.4% net margin).
Dividend & Returns
Yes, Pfizer Inc. (PFE) pays a dividend with a yield of 6.81%. This makes it attractive for income-focused investors.
Pfizer Inc. (PFE) has a return on equity (ROE) of 8.9%. This is below average, suggesting room for improvement.
Pfizer Inc. (PFE) generated $9.48B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.